Drug General Information
Drug ID	D07QFU
Former ID	DIB011212
Drug Name	T-607
Drug Type	Small molecular drug
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 2	[521548]
Company	Tularik Inc
Structure		Download 2D MOL 3D MOL
Formula	C5H11NOS3
CAS Number	CAS 261944-52-9
PubChem Compound ID	462014
Target and Pathway
Target(s)	Tubulin beta	Target Info	Inhibitor	[551628]
KEGG Pathway	Phagosome
	Gap junction
	Pathogenic Escherichia coli infection
NetPath Pathway	FSH Signaling Pathway
	TCR Signaling Pathway
	EGFR1 Signaling Pathway
PANTHER Pathway	Cytoskeletal regulation by Rho GTPase
	Huntington disease
Reactome	Regulation of PLK1 Activity at G2/M Transition
	Loss of Nlp from mitotic centrosomes
	Recruitment of mitotic centrosome proteins and complexes
	Loss of proteins required for interphase microtubule organization?from the centrosome
	Anchoring of the basal body to the plasma membrane
WikiPathways	Parkin-Ubiquitin Proteasomal System pathway
	Pathogenic Escherichia coli infection
	Mitotic G2-G2/M phases
References
Ref 521548	ClinicalTrials.gov (NCT00054249) T900607 in Treating Patients With Gastroesophageal Junction Cancer. U.S. National Institutes of Health.
Ref 551628	Nucleophilic reactions of N-ethoxycarbonyliminopyridinium ylide with alpha,beta-unsaturated carbonyl compounds. Volume 28, Issue 6, 1972, Pages 1469-1476.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.